Hims & Hers Health, Inc. (NYSE:HIMS) Insider Soleil Boughton Sells 54,153 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 54,153 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $29.90, for a total value of $1,619,174.70. Following the transaction, the insider now directly owns 165,650 shares in the company, valued at $4,952,935. This trade represents a 24.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Soleil Boughton also recently made the following trade(s):

• On Monday, January 6th, Soleil Boughton sold 268,932 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.75, for a total transaction of $7,462,863.00.
• On Tuesday, November 26th, Soleil Boughton sold 2,343 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.90, for a total transaction of $70,055.70.
• On Tuesday, October 29th, Soleil Boughton sold 2,339 shares of Hims & Hers Health stock. The shares were sold at an average price of $23.16, for a total transaction of $54,171.24.

Hims & Hers Health Stock Up 4.0 %

NYSE:HIMS opened at $30.90 on Friday. Hims & Hers Health, Inc. has a 52 week low of $8.51 and a 52 week high of $35.02. The stock has a market cap of $6.75 billion, a price-to-earnings ratio of 70.22 and a beta of 1.31. The company’s 50 day moving average price is $27.98 and its 200-day moving average price is $22.09.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. During the same period last year, the business posted ($0.04) EPS. The company’s revenue was up 77.1% compared to the same quarter last year. As a group, sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Institutional Investors Weigh In On Hims & Hers Health

Large investors have recently bought and sold shares of the business. Raleigh Capital Management Inc. lifted its stake in Hims & Hers Health by 1,100.0% during the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 1,100 shares during the period. GAMMA Investing LLC raised its holdings in shares of Hims & Hers Health by 2,173.7% during the fourth quarter. GAMMA Investing LLC now owns 2,251 shares of the company’s stock valued at $54,000 after purchasing an additional 2,152 shares during the last quarter. Quest Partners LLC lifted its position in Hims & Hers Health by 22.6% during the third quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock valued at $81,000 after purchasing an additional 807 shares during the period. Nisa Investment Advisors LLC boosted its holdings in Hims & Hers Health by 115.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 4,560 shares of the company’s stock worth $110,000 after purchasing an additional 2,442 shares during the last quarter. Finally, Ausbil Investment Management Ltd purchased a new stake in Hims & Hers Health in the fourth quarter worth approximately $127,000. 63.52% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

HIMS has been the topic of several research reports. Canaccord Genuity Group lifted their price objective on Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a research report on Monday, December 2nd. Piper Sandler lifted their price target on Hims & Hers Health from $21.00 to $24.00 and gave the company a “neutral” rating in a research report on Monday, January 6th. BTIG Research assumed coverage on Hims & Hers Health in a report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price objective for the company. Deutsche Bank Aktiengesellschaft raised their price objective on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research report on Wednesday, November 6th. Finally, Citigroup downgraded shares of Hims & Hers Health from a “neutral” rating to a “sell” rating and upped their target price for the stock from $24.00 to $25.00 in a research report on Friday, January 10th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $25.13.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.